All patients in high-risk primary or secondary prevention should be treated with lipid-lowering drugs, regardless of their cholesterol levels. Groundbreaking results from the Heart Protection Study
pp 581-583
Downloads
Published
2026-03-02
Issue
Section
CARDIOLOGICAL NEWS
License
Copyright (c) 2026 Argentine Journal of Cardiology

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.







